07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: S. aureus monofunctional glycosyltransferase

Infectious disease INDICATION: Bacterial infection; Enterococcus; Staphylococcus; Streptococcus In vitro and mouse studies identified bacterial monofunctional glycosyltransferase inhibitors that could help treat bacterial infections. Chemical synthesis and in vitro testing of monosaccharide-based compounds identified two compounds that...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Alchemia, Panther Biotechnology deal

Panther will acquire Alchemia’s Alchemia Oncology Pty Ltd. subsidiary in a deal slated to close by late October. The subsidiary’s portfolio includes the HyACT drug delivery technology and HA-Irinotecan for cancer. This year, Panther...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Alchemia management update

Alchemia Ltd. (ASX:ACL), Brisbane, Australia   Business: Chemistry, Cancer, Hematology   Departed: Thomas Liquard as CEO   ...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

HA-Irinotecan: Phase III data

The double-blind, Australian Phase III ACO002 trial in 415 irinotecan-naive patients who failed previous therapy showed that HA-Irinotecan as part of FOLFIRI therapy as second- or third-line treatment missed the primary endpoint of improving median...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Imugene management update

Imugene Ltd. (ASX:IMU), Armadale, Australia   Business: Drug delivery   Hired: Charles Walker as CEO, formerly CEO of Alchemia Ltd.   ...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Alchemia management update

Alchemia Ltd. (ASX:ACL), Brisbane, Australia   Business: Chemistry, Cancer, Hematology   Hired: Jenni Pilcher as CFO, formerly secretary and CFO of Mesoblast Ltd.   ...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Mesoblast management update

Mesoblast Ltd. (ASX:MSB; Pink:MBLTY), Melbourne, Australia   Business: Gene/Cell therapy   Hired: Paul Hodgkinson as CFO, formerly CFO of Novartis AG’s Australia and New Zealand group; he succeeds Jenni Pilcher, who became CFO of Alchemia Ltd....
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Summer lull

With Vertex Pharmaceuticals Inc. already having delivered 2014's most anticipated data and Gilead Sciences Inc. having rolled out the year's most keenly watched launch, buysiders expect a quiet 3Q14 and plan to use the lull...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

HA-Irinotecan: Phase II started

Alchemia said investigators began the Australian Phase II CHIME trial to evaluate HA-Irinotecan as part of FOLFIRI chemotherapy plus Erbitux cetuximab in about 50 patients with mCRC. HA-Irinotecan is in Phase III testing to...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

HA-Irinotecan: Phase III ongoing

Alchemia said it now expects to report top-line data from the double-blind, international Phase III ACO002 trial of HA-Irinotecan before the end of 3Q14. The company, which previously said it expected data this half, said...